ATE539763T1 - Verwendung des nervenwachstumfaktors in augentropfen zur behandlung von erkrankungen des zentralen nervensystems, wie z.b. alzheimer- krankheit und parkinson-krankheit - Google Patents
Verwendung des nervenwachstumfaktors in augentropfen zur behandlung von erkrankungen des zentralen nervensystems, wie z.b. alzheimer- krankheit und parkinson-krankheitInfo
- Publication number
- ATE539763T1 ATE539763T1 AT06780613T AT06780613T ATE539763T1 AT E539763 T1 ATE539763 T1 AT E539763T1 AT 06780613 T AT06780613 T AT 06780613T AT 06780613 T AT06780613 T AT 06780613T AT E539763 T1 ATE539763 T1 AT E539763T1
- Authority
- AT
- Austria
- Prior art keywords
- disease
- parkinson
- alzheimer
- growth factor
- nervous system
- Prior art date
Links
- 102000015336 Nerve Growth Factor Human genes 0.000 title abstract 4
- 108010025020 Nerve Growth Factor Proteins 0.000 title abstract 4
- 229940053128 nerve growth factor Drugs 0.000 title abstract 4
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- 208000018737 Parkinson disease Diseases 0.000 title abstract 2
- 210000003169 central nervous system Anatomy 0.000 title abstract 2
- 239000003889 eye drop Substances 0.000 title abstract 2
- 229940012356 eye drops Drugs 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000007170 pathology Effects 0.000 abstract 3
- 210000005013 brain tissue Anatomy 0.000 abstract 2
- 241001573498 Compacta Species 0.000 abstract 1
- 210000001638 cerebellum Anatomy 0.000 abstract 1
- 210000003710 cerebral cortex Anatomy 0.000 abstract 1
- 210000001320 hippocampus Anatomy 0.000 abstract 1
- 210000001577 neostriatum Anatomy 0.000 abstract 1
- 239000002674 ointment Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 210000004129 prosencephalon Anatomy 0.000 abstract 1
- 210000003523 substantia nigra Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000447A ITRM20050447A1 (it) | 2005-08-19 | 2005-08-19 | Uso del nerve growth factor in collirio nella terapia di patologie del sistema nervoso centrale, quali la malattia di alzheimer e il morbo di parkinson. |
| PCT/IT2006/000620 WO2007020672A2 (en) | 2005-08-19 | 2006-08-11 | Use of nerve growth factor in eye-drops for therapy of pathologies of the central nervous system, such as alzheimer's and parkinson's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE539763T1 true ATE539763T1 (de) | 2012-01-15 |
Family
ID=37667295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06780613T ATE539763T1 (de) | 2005-08-19 | 2006-08-11 | Verwendung des nervenwachstumfaktors in augentropfen zur behandlung von erkrankungen des zentralen nervensystems, wie z.b. alzheimer- krankheit und parkinson-krankheit |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20090118177A1 (de) |
| EP (1) | EP1948217B1 (de) |
| JP (1) | JP2009504724A (de) |
| AT (1) | ATE539763T1 (de) |
| CA (1) | CA2619721A1 (de) |
| DK (1) | DK1948217T3 (de) |
| ES (1) | ES2376992T3 (de) |
| IL (1) | IL189605A (de) |
| IT (1) | ITRM20050447A1 (de) |
| RU (1) | RU2429007C2 (de) |
| WO (1) | WO2007020672A2 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101760139B1 (ko) * | 2007-06-29 | 2017-07-31 | 클라렌슈 피티와이 리미티드 | 안투여를 통한 신경 또는 신경정신 장애의 치료 또는 예방용 약학 조성물 |
| CN101972224B (zh) * | 2010-09-13 | 2012-01-04 | 舒泰神(北京)生物制药股份有限公司 | 一种眼用原位凝胶 |
| IT202000032423A1 (it) | 2020-12-24 | 2022-06-24 | Univ Degli Studi Di Trieste | Metodo per la produzione di forme processate proteoliticamente di fattori trofici o fattori di crescita |
| BR112023023249A2 (pt) * | 2021-05-07 | 2024-01-23 | Oyster Point Pharma Inc | Fator neurotrófico de codificação de vírion aav e usos do mesmo |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4959319A (en) * | 1985-08-01 | 1990-09-25 | Skelnik Debra L | Process of corneal enhancement |
| US4973466A (en) * | 1988-06-21 | 1990-11-27 | Chiron Ophthalmics, Inc. | Wound-healing dressings and methods |
| US5767079A (en) * | 1992-07-08 | 1998-06-16 | Celtrix Pharmaceuticals, Inc. | Method of treating ophthalmic disorders using TGF -β |
| US5770577A (en) * | 1994-11-14 | 1998-06-23 | Amgen Inc. | BDNF and NT-3 polypeptides selectively linked to polyethylene glycol |
| US5641750A (en) * | 1995-11-29 | 1997-06-24 | Amgen Inc. | Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product |
| US6063757A (en) * | 1995-11-29 | 2000-05-16 | Urso; Richard G. | Wound treatment method with nerve growth factor |
| US5641749A (en) * | 1995-11-29 | 1997-06-24 | Amgen Inc. | Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product |
| IT1283911B1 (it) * | 1996-02-05 | 1998-05-07 | Farmigea Spa | Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo |
| US6299895B1 (en) * | 1997-03-24 | 2001-10-09 | Neurotech S.A. | Device and method for treating ophthalmic diseases |
| WO1998010785A1 (en) * | 1996-09-13 | 1998-03-19 | Advanced Medicine Research Institute | Ophthalmic compositions of neurotrophic factors, remedies for optic nerve function disorders and method for treating optic nerve function disorders |
| IT1291892B1 (it) * | 1997-04-24 | 1999-01-21 | Alessandro Lambiase | Uso del nerve growth factor nella conservazione di cornee in coltura, nella produzione di tessuti corneali e congiuntivali in vitro e nella |
| AU8559398A (en) * | 1998-08-05 | 2000-02-28 | Advanced Medicine Research Institute | Remedies for cerebral central lesions with the use of neurotrophic factors |
| EP1135105B1 (de) * | 1998-12-09 | 2005-03-02 | Chiron Corporation | Verwendung eines neurologischen wirkstoffes zur herstellung eines medikamentes zur behandlung von erkrankungen des zentralen nervensystems |
| IT1305294B1 (it) * | 1999-01-29 | 2001-05-04 | Alessandro Lambiase | Uso del nerve growth factor nella terapia di patologie a carico deitessuti intraoculari. |
| US20020009498A1 (en) * | 1999-11-05 | 2002-01-24 | Guy L. Clifton | Methods and compositions for treatment of traumatic brain injury |
| IL147921A0 (en) * | 2002-01-31 | 2002-08-14 | Abdulrazik Mohammad | A method for treating central nervous system disorders by ocular dosing |
| RU2251429C2 (ru) * | 2002-12-30 | 2005-05-10 | Институт Молекулярной Генетики Российской Академии Наук (Имг Ран) | Фармацевтическая композиция для лечения ишемического инсульта и способ лечения |
-
2005
- 2005-08-19 IT IT000447A patent/ITRM20050447A1/it unknown
-
2006
- 2006-08-11 US US12/064,172 patent/US20090118177A1/en not_active Abandoned
- 2006-08-11 RU RU2008110505/15A patent/RU2429007C2/ru not_active IP Right Cessation
- 2006-08-11 AT AT06780613T patent/ATE539763T1/de active
- 2006-08-11 DK DK06780613.3T patent/DK1948217T3/da active
- 2006-08-11 EP EP06780613A patent/EP1948217B1/de not_active Expired - Lifetime
- 2006-08-11 CA CA002619721A patent/CA2619721A1/en not_active Abandoned
- 2006-08-11 WO PCT/IT2006/000620 patent/WO2007020672A2/en not_active Ceased
- 2006-08-11 JP JP2008526617A patent/JP2009504724A/ja not_active Ceased
- 2006-08-11 ES ES06780613T patent/ES2376992T3/es not_active Expired - Lifetime
-
2008
- 2008-02-19 IL IL189605A patent/IL189605A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IL189605A (en) | 2013-10-31 |
| DK1948217T3 (da) | 2012-02-20 |
| WO2007020672A3 (en) | 2007-05-31 |
| ES2376992T3 (es) | 2012-03-21 |
| RU2429007C2 (ru) | 2011-09-20 |
| CA2619721A1 (en) | 2007-02-22 |
| ITRM20050447A1 (it) | 2007-02-20 |
| WO2007020672A2 (en) | 2007-02-22 |
| EP1948217B1 (de) | 2012-01-04 |
| RU2008110505A (ru) | 2009-09-27 |
| IL189605A0 (en) | 2008-06-05 |
| US20090118177A1 (en) | 2009-05-07 |
| EP1948217A2 (de) | 2008-07-30 |
| JP2009504724A (ja) | 2009-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Su et al. | Enhancing brain plasticity to promote stroke recovery | |
| Koshimori et al. | Future perspectives on neural mechanisms underlying rhythm and music based neurorehabilitation in Parkinson’s disease | |
| Fisher et al. | AF150 (S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer’s disease | |
| Zhou et al. | Current evidence, clinical applications, and future directions of transcranial magnetic stimulation as a treatment for ischemic stroke | |
| Wang et al. | Therapeutic strategies for Parkinson’s disease: the ancient meets the future—traditional Chinese herbal medicine, electroacupuncture, gene therapy and stem cells | |
| BR112015020391A2 (pt) | gama-dicetonas como ativadoras da via de sinalização de wnt/beta-catenina | |
| MX2012010657A (es) | Compuestos de espiro amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso medico. | |
| Wei et al. | Geniposide attenuates epilepsy symptoms in a mouse model through the PI3K/Akt/GSK-3β signaling pathway | |
| Nam et al. | Acupuncture stimulation induces neurogenesis in adult brain | |
| Guo et al. | Use of transcutaneous auricular vagus nerve stimulation as an adjuvant therapy for the depressive symptoms of COVID-19: A literature review | |
| Billeri et al. | A narrative review on non-invasive stimulation of the cerebellum in neurological diseases | |
| Gao et al. | Enhancement of neural regeneration as a therapeutic strategy for Alzheimer's disease | |
| IL189605A0 (en) | Use of nerve growth factor in eye-drops for therapy of pathologies of the central nervous system, such as alzheimer's and parkinson's disease | |
| JOP20240081A1 (ar) | مُعدِّلات الجزيئات الصغيرة لنشاط الجلوكوسيريبروسيد واستخداماتها | |
| Cavalli et al. | Role of acupuncture in the management of severe acquired brain injuries (sABIs) | |
| Calne | Parkinsonism: Clinical and neuropharmacologic aspects | |
| Georgescu Margarint et al. | Reduced interhemispheric coherence in cerebellar kainic acid-induced lateralized dystonia | |
| Doshi et al. | Deep Brain Stimulation for Parkinson's Disease: Currents Status and Emerging Concepts | |
| Gao et al. | Roles of p75NTR in Maintaining Brain Hemostasis and the Implications for p75NTR-targeted Therapies | |
| Huang et al. | 2017 yearbook of neurorestoratology | |
| Poniatowski et al. | Dose-ranging effects of the intracerebral administration of atsttrin in experimental model of Parkinson’s disease induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) in mice | |
| Lee et al. | The fundamental mechanism of transcranial electrical stimulation in post-stroke rehabilitation | |
| Bernert et al. | Effects of a single transdermal nicotine dose on cognitive performance in adults with Down syndrome | |
| Jiao | Embryonic and adult neural stem cell research in China | |
| WO2014068171A1 (en) | N-substituted 4-aminophenols and corresponding quinone imines |